BioCryst Pharma (BCRX) Misses Q1 EPS by 8c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $4.58 --0%
EPS Growth %: +25.0%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
ESCA, LICT, NKSH, More
EPS Growth %: +25.0%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
ESCA, LICT, NKSH, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.31), $0.08 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $4.82 million versus the consensus estimate of $5.42 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Iridium Communications (IRDM) Reports In-Line Q1 EPS; offers outlook
- BioCryst Pharma (BCRX) Announces Approval of ORLADEYO in Brazil
- Nokia slightly down as Q1 profit growth fails to meet consensus; outlook unchanged
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
